Le Lézard
Classified in: Health
Subject: ACC

Orcas Naturals, Inc. and Unique Encapsulation Technology, LLC Receive UL Inspection and Conformance Certifications


LANDING, New Jersey, Sept. 13, 2018 /PRNewswire/ -- Orcas Naturals, Inc. and Unique Encapsulation Technology, LLC, (UET) are proud to announce they have attained 21 CFR 111:4-2-16 certification in accordance with the Retail Certification Program.  This means that their joint facility at 9 Lenel Rd. in Landing, NJ, was audited by UL Registrar, LLC, using an accredited certification process to determine that the organization is found in conformance with Good Manufacturing Practice (GMP) guidelines, 21 CFR 111:4-2016.

Orcas Naturals, Inc. and Unique Encapsulation Technology, LLC receive UL Inspection and Conformance Certifications

GMPs are guidelines that provide a system of processes, procedures, and documentation to assure a product has the identity, strength, composition, quality, and purity that appear on the product label. These GMP requirements are listed under FD&C Act section 520(f).

The UL Registrar LLC GMP Certification Program enables manufactures to become independently registered by UL to meet GMP requirements for the manufacturing, packaging, holding, and distribution of finished products, components, ingredients, and/or raw materials. "Conformance to the UL standard adds credence to our in-house QC laboratory protocols and vendor qualification measures, helping us demonstrate our commitment to public safety," says K G Rao, President of Orcas Naturals and UET.

The certification covers the Landing, NJ, location and includes the manufacturing, packaging, warehousing, and distribution of dietary supplements as raw materials as well as powders and liquid-filled capsules.

Orcas Naturals and UET created a strategic alliance that provides clients with one-stop service for turnkey ingredient sourcing, conventional and customized formulations, and unique filling technologies.

"The UL GMP certification for facility operation and management systems holds us accountable to our vision of delivering quality ingredients in state of the art capsules," notes Rao.."We fulfill a unique niche in our market, offering small batch sizes, delivering rapid turnaround times and leading with a strong team of quality professionals. As an industry authority, GMP status strengthens our customers' confidence in our mission to help them differentiate their final product in a competitive market."

For more information, contact:

Company contact:

Press Contact:

Orcas Naturals

NutriPR

Vijay Khadse

Liat Simha

Quality Director

Tel: +972-9-9742893

E-mail: [email protected]

E-mail: [email protected]

Website: www.orcasnaturals.com

Website: www.nutripr.com


Twitter: @LiatSimha

 

SOURCE Orcas Naturals, Inc.; Unique Encapsulation Technology


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: